{"id":"NCT01772472","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)","officialTitle":"A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-03","primaryCompletion":"2018-07-25","completion":"2024-05-23","firstPosted":"2013-01-21","resultsPosted":"2019-10-01","lastUpdate":"2025-07-22"},"enrollment":1486,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"trastuzumab","otherNames":[]},{"type":"DRUG","name":"trastuzumab emtansine","otherNames":[]}],"arms":[{"label":"Trastuzumab","type":"ACTIVE_COMPARATOR"},{"label":"Trastuzumab emtansine","type":"EXPERIMENTAL"}],"summary":"This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.","primaryOutcome":{"measure":"Invasive Disease-free Survival (IDFS) Rate at 3 Years","timeFrame":"At Year 3","effectByArm":[{"arm":"Trastuzumab","deltaMin":77.12,"sd":null},{"arm":"Trastuzumab Emtansine","deltaMin":88.44,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":16},"locations":{"siteCount":268,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","China","Colombia","Czechia","France","Germany","Greece","Guatemala","Hong Kong","Ireland","Israel","Italy","Mexico","Panama","Peru","Serbia","South Africa","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39813643","30516102"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":720},"commonTop":["FATIGUE","NAUSEA","RADIATION SKIN INJURY","ARTHRALGIA","HEADACHE"]}}